United States  

Moderna announces positive Phase 1 trial data for coronavirus vaccine

CBS News Monday, 18 May 2020
The biotech firm Moderna Therapeutics announced that the first eight participants in the Phase 1 of its COVID-19 vaccine trial developed some antibodies after a single dose. Moderna is now expected to start a second round of clinical trials as soon as next month. Dr. David Agus joined "CBS This Morning" to explain the development and the latest in the race for a vaccine.
0
shares
ShareTweetSavePostSend
 
Video Credit: Wochit Entertainment - Published
News video: Moderna Early Vaccine Sees Positive Results

Moderna Early Vaccine Sees Positive Results 00:25

Business Insider reports that a coronavirus vaccine my not be ready until the end of 2021, according to Roche, the world's second-largest pharmaceutical company. He explained "According to the most likely scenario, we will not have a vaccination before the end of next year." Instead, Severin Schwan,...

You Might Like


Related videos from verified sources

Cambridge Biotech Company Moderna Begins Second Stage Of Coronavirus Vaccine Study [Video]

Cambridge Biotech Company Moderna Begins Second Stage Of Coronavirus Vaccine Study

WBZ-TV's Ken MacLeod reports.

Credit: WBZ CBS Boston     Duration: 00:24Published
Coronavirus Vaccine From China Is Safe In Early Trial [Video]

Coronavirus Vaccine From China Is Safe In Early Trial

A coronavirus vaccine developed by CanSino Biologics Inc appears to be safe. It induced a rapid immune response in its first human trial, Reuters reports. This vaccine did not cause any serious adverse..

Credit: Wochit Business     Duration: 00:39Published
Arcturus CEO on Vaccine Candidate, Moderna's Vaccine [Video]

Arcturus CEO on Vaccine Candidate, Moderna's Vaccine

Arcturus CEO Joe Payne breaks down Arcturus Therapeutics vaccine candidate and Moderna's vaccine candidate.

Credit: The Street     Duration: 01:16Published

Related news from verified sources

Moderna hit by criticism over lack of data on coronavirus vaccine candidate results

Moderna Inc (NASDAQ:MRNA) was lower in premarket New York trading on Wednesday as the stock still suffers criticism over the most recent results for its...
Proactive Investors

Moderna sees 'positive' Phase I data for potential coronavirus vaccine

Biotech company Moderna announced on Monday that its COVID-19 vaccine produced antibodies in all 45 participants in a trial, a significant milestone in the fight...
FOXNews.com

Dow slides 391 points on reports that Moderna's COVID-19 vaccine study lacked key data

Dow slides 391 points on reports that Moderna's COVID-19 vaccine study lacked key data
· *US indexes slid in late trading on Tuesday after a report said Moderna's highly touted results from a phase-one trial of its coronavirus vaccine candidate...
Business Insider Also reported by •bizjournals

Tweets about this